PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1507205-3 1992 In addition, AdoMet-DC activity could not be restored following extensive dialysis of the enzyme-inhibitor complex, and the enzyme was protected from irreversible inactivation by the known competitive inhibitor methylglyoxal bis(guanylhydrazone). Mitoguazone 229-244 adenosylmethionine decarboxylase 1 Homo sapiens 13-22 25046760-5 2014 Methylglyoxal-bis(guanylhydrazone) (MGBG), an inhibitor of SAMDC resulting in the inability of activated cells to synthesize Spd and Spm, exacerbates the negative effects induced by drought. Mitoguazone 0-34 adenosylmethionine decarboxylase 1 Homo sapiens 59-64 25046760-5 2014 Methylglyoxal-bis(guanylhydrazone) (MGBG), an inhibitor of SAMDC resulting in the inability of activated cells to synthesize Spd and Spm, exacerbates the negative effects induced by drought. Mitoguazone 36-40 adenosylmethionine decarboxylase 1 Homo sapiens 59-64 8557774-7 1996 Treatment of these cells with methylglyoxal bis(guanylhydrazone) (MGBG), an AdoMetDC inhibitor which enters cell using polyamine transport system, shows no inhibition of cell growth. Mitoguazone 66-70 adenosylmethionine decarboxylase 1 Homo sapiens 76-84 8205541-1 1994 Inhibitors of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), derived from methylglyoxal-bis(guanylhydrazone) (MGBG), have been shown to have significant antitumor activity in several human solid tumor systems (U. Regenass et al., Cancer Res., 52:4712-4718, 1992). Mitoguazone 105-139 adenosylmethionine decarboxylase 1 Homo sapiens 48-82 8205541-1 1994 Inhibitors of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), derived from methylglyoxal-bis(guanylhydrazone) (MGBG), have been shown to have significant antitumor activity in several human solid tumor systems (U. Regenass et al., Cancer Res., 52:4712-4718, 1992). Mitoguazone 105-139 adenosylmethionine decarboxylase 1 Homo sapiens 84-89 8205541-1 1994 Inhibitors of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), derived from methylglyoxal-bis(guanylhydrazone) (MGBG), have been shown to have significant antitumor activity in several human solid tumor systems (U. Regenass et al., Cancer Res., 52:4712-4718, 1992). Mitoguazone 141-145 adenosylmethionine decarboxylase 1 Homo sapiens 48-82 8205541-1 1994 Inhibitors of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), derived from methylglyoxal-bis(guanylhydrazone) (MGBG), have been shown to have significant antitumor activity in several human solid tumor systems (U. Regenass et al., Cancer Res., 52:4712-4718, 1992). Mitoguazone 141-145 adenosylmethionine decarboxylase 1 Homo sapiens 84-89 1480164-8 1992 The specificity of labeling of AdoMetDC by this procedure was confirmed by the prevention of 35S-decarboxylated S-adenosylmethionine (AdoMet) binding in the presence of specific AdoMetDC inhibitors [either methylglyoxal bis(guanylhydrazone (MGBG), a reversible inhibitor, or 5"-deoxy-5"-[(2-hydrazinoethyl)methylamino]adenosine (MHZEA), an irreversible inactivator]. Mitoguazone 206-239 adenosylmethionine decarboxylase 1 Homo sapiens 31-39 1480164-8 1992 The specificity of labeling of AdoMetDC by this procedure was confirmed by the prevention of 35S-decarboxylated S-adenosylmethionine (AdoMet) binding in the presence of specific AdoMetDC inhibitors [either methylglyoxal bis(guanylhydrazone (MGBG), a reversible inhibitor, or 5"-deoxy-5"-[(2-hydrazinoethyl)methylamino]adenosine (MHZEA), an irreversible inactivator]. Mitoguazone 241-245 adenosylmethionine decarboxylase 1 Homo sapiens 31-39 1480164-9 1992 As compared to human AdoMetDC, the trypanosomal enzyme showed weaker binding to a column of MGBG-Sepharose and also was significantly less sensitive to inhibition by MGBG and its congener ethylglyoxal bis(guanylhydrazone) (EGBG). Mitoguazone 92-96 adenosylmethionine decarboxylase 1 Homo sapiens 21-29 1480164-9 1992 As compared to human AdoMetDC, the trypanosomal enzyme showed weaker binding to a column of MGBG-Sepharose and also was significantly less sensitive to inhibition by MGBG and its congener ethylglyoxal bis(guanylhydrazone) (EGBG). Mitoguazone 166-170 adenosylmethionine decarboxylase 1 Homo sapiens 21-29 10944598-2 2000 SAM486A (CGP 48664) is a new inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), more potent and specific than the first-generation SAMDC inhibitor methylglyoxal (bis) guanylhydrazone (MGBG). Mitoguazone 187-222 adenosylmethionine decarboxylase 1 Homo sapiens 112-117 10944598-2 2000 SAM486A (CGP 48664) is a new inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), more potent and specific than the first-generation SAMDC inhibitor methylglyoxal (bis) guanylhydrazone (MGBG). Mitoguazone 224-228 adenosylmethionine decarboxylase 1 Homo sapiens 76-110 10944598-2 2000 SAM486A (CGP 48664) is a new inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC), more potent and specific than the first-generation SAMDC inhibitor methylglyoxal (bis) guanylhydrazone (MGBG). Mitoguazone 224-228 adenosylmethionine decarboxylase 1 Homo sapiens 112-117 9880821-9 1998 SAMDC inhibitor, methylglyoxal-bis-guanylhydrazone, induced growth arrest which was not reversed by exogenous putrescine, but only by high concentrations of spermidine. Mitoguazone 17-50 adenosylmethionine decarboxylase 1 Homo sapiens 0-5 9677309-11 1998 Methylglyoxal-bis(guanylhydrazone) (MGBG), a potent inhibitor of human AdoMetDC, was a poor inhibitor of the T. cruzi enzyme. Mitoguazone 0-34 adenosylmethionine decarboxylase 1 Homo sapiens 71-79 9677309-11 1998 Methylglyoxal-bis(guanylhydrazone) (MGBG), a potent inhibitor of human AdoMetDC, was a poor inhibitor of the T. cruzi enzyme. Mitoguazone 36-40 adenosylmethionine decarboxylase 1 Homo sapiens 71-79 9677309-12 1998 This differential sensitivity to MGBG suggests that the two enzymes are sufficiently different to warrant the search for compounds that might interfere with the progression of Chagas" disease by selectively inhibiting T. cruzi AdoMetDC. Mitoguazone 33-37 adenosylmethionine decarboxylase 1 Homo sapiens 227-235 8877009-11 1996 These data demonstrate structure-activity relationships of a series of MGBG derivatives on cell growth, enzyme activities, and polyamine biosynthesis in a hormone-responsive breast cancer cell line and suggest potential application of SAMDC inhibitors as therapeutic agents. Mitoguazone 71-75 adenosylmethionine decarboxylase 1 Homo sapiens 235-240 1511437-1 1992 Methylglyoxal bis(guanylhydrazone) (MGBG) has been studied clinically as an antitumor and antileukemic agent and is recognized as a potent but nonspecific inhibitor of the key polyamine biosynthetic enzyme, S-adenosylmethionine decarboxylase (SAMDC). Mitoguazone 0-34 adenosylmethionine decarboxylase 1 Homo sapiens 207-241 1511437-1 1992 Methylglyoxal bis(guanylhydrazone) (MGBG) has been studied clinically as an antitumor and antileukemic agent and is recognized as a potent but nonspecific inhibitor of the key polyamine biosynthetic enzyme, S-adenosylmethionine decarboxylase (SAMDC). Mitoguazone 0-34 adenosylmethionine decarboxylase 1 Homo sapiens 243-248 1511437-1 1992 Methylglyoxal bis(guanylhydrazone) (MGBG) has been studied clinically as an antitumor and antileukemic agent and is recognized as a potent but nonspecific inhibitor of the key polyamine biosynthetic enzyme, S-adenosylmethionine decarboxylase (SAMDC). Mitoguazone 36-40 adenosylmethionine decarboxylase 1 Homo sapiens 207-241 1511437-1 1992 Methylglyoxal bis(guanylhydrazone) (MGBG) has been studied clinically as an antitumor and antileukemic agent and is recognized as a potent but nonspecific inhibitor of the key polyamine biosynthetic enzyme, S-adenosylmethionine decarboxylase (SAMDC). Mitoguazone 36-40 adenosylmethionine decarboxylase 1 Homo sapiens 243-248 1511437-2 1992 A series of four SAMDC inhibitors with structural features similar to MGBG have been found to have improved potency and specificity toward the target enzyme, SAMDC. Mitoguazone 70-74 adenosylmethionine decarboxylase 1 Homo sapiens 17-22 1511437-2 1992 A series of four SAMDC inhibitors with structural features similar to MGBG have been found to have improved potency and specificity toward the target enzyme, SAMDC. Mitoguazone 70-74 adenosylmethionine decarboxylase 1 Homo sapiens 158-163 1511437-3 1992 Relative to MGBG, the new derivatives were much more effective in inhibiting partially purified preparations of SAMDC (50% inhibitory concentration, 10 to 100 nM), much less effective at inhibiting diamine oxidase, and inactive toward ornithine decarboxylase. Mitoguazone 12-16 adenosylmethionine decarboxylase 1 Homo sapiens 112-117 1637820-1 1992 Human S-adenosylmethionine decarboxylase (AdoMetDC) was expressed in high yield in Escherichia coli using the pIN-III(lppP-5) expression vector and purified to apparent homogeneity using affinity chromatography on methylglyoxal bis(guanylhydrazone)-Sepharose. Mitoguazone 214-248 adenosylmethionine decarboxylase 1 Homo sapiens 6-40 1637820-1 1992 Human S-adenosylmethionine decarboxylase (AdoMetDC) was expressed in high yield in Escherichia coli using the pIN-III(lppP-5) expression vector and purified to apparent homogeneity using affinity chromatography on methylglyoxal bis(guanylhydrazone)-Sepharose. Mitoguazone 214-248 adenosylmethionine decarboxylase 1 Homo sapiens 42-50 3778524-0 1986 Ornithine decarboxylase and spermidine/spermine N1-acetyltransferase are induced in K562 cells by S-adenosylmethionine decarboxylase inhibitor methylglyoxal bis(guanylhydrazone) but not by analogous methylglyoxal bis(butylamidinohydrazone). Mitoguazone 143-176 adenosylmethionine decarboxylase 1 Homo sapiens 98-132 3778524-1 1986 The activities of ornithine decarboxylase (ODC) and spermidine/spermine N1-acetyltransferase (SAT) were increased by the addition of S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor methylglyoxal bis(guanylhydrazone) (MGBG) in cultured human erythroid leukemia K 562 cells. Mitoguazone 189-223 adenosylmethionine decarboxylase 1 Homo sapiens 133-167 3778524-1 1986 The activities of ornithine decarboxylase (ODC) and spermidine/spermine N1-acetyltransferase (SAT) were increased by the addition of S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor methylglyoxal bis(guanylhydrazone) (MGBG) in cultured human erythroid leukemia K 562 cells. Mitoguazone 189-223 adenosylmethionine decarboxylase 1 Homo sapiens 169-177 3778524-1 1986 The activities of ornithine decarboxylase (ODC) and spermidine/spermine N1-acetyltransferase (SAT) were increased by the addition of S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor methylglyoxal bis(guanylhydrazone) (MGBG) in cultured human erythroid leukemia K 562 cells. Mitoguazone 225-229 adenosylmethionine decarboxylase 1 Homo sapiens 133-167 3778524-1 1986 The activities of ornithine decarboxylase (ODC) and spermidine/spermine N1-acetyltransferase (SAT) were increased by the addition of S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor methylglyoxal bis(guanylhydrazone) (MGBG) in cultured human erythroid leukemia K 562 cells. Mitoguazone 225-229 adenosylmethionine decarboxylase 1 Homo sapiens 169-177 3778524-6 1986 On the other hand, methylglyoxal bis(butylamidinohydrazone) (MGBB), a derivative of MGBG inhibiting AdoMetDC effectively, did not induce ODC or SAT activities. Mitoguazone 84-88 adenosylmethionine decarboxylase 1 Homo sapiens 100-108 3455877-1 1986 Methylglyoxal bis(butylamidinohydrazone) (MGBB) inhibited S-adenosylmethionine decarboxylase (SAMDC) activity competitively with S-adenosylmethionine (SAM) showing the Ki value of 1.8 X 10(-5) M. MGBB showed less SAMDC-stabilizing effect in rat liver in vivo than did methylglyoxal bis-(guanylhydrazone) (MGBG). Mitoguazone 268-303 adenosylmethionine decarboxylase 1 Homo sapiens 58-92 3455877-1 1986 Methylglyoxal bis(butylamidinohydrazone) (MGBB) inhibited S-adenosylmethionine decarboxylase (SAMDC) activity competitively with S-adenosylmethionine (SAM) showing the Ki value of 1.8 X 10(-5) M. MGBB showed less SAMDC-stabilizing effect in rat liver in vivo than did methylglyoxal bis-(guanylhydrazone) (MGBG). Mitoguazone 268-303 adenosylmethionine decarboxylase 1 Homo sapiens 94-99 3455877-1 1986 Methylglyoxal bis(butylamidinohydrazone) (MGBB) inhibited S-adenosylmethionine decarboxylase (SAMDC) activity competitively with S-adenosylmethionine (SAM) showing the Ki value of 1.8 X 10(-5) M. MGBB showed less SAMDC-stabilizing effect in rat liver in vivo than did methylglyoxal bis-(guanylhydrazone) (MGBG). Mitoguazone 305-309 adenosylmethionine decarboxylase 1 Homo sapiens 58-92 3455877-1 1986 Methylglyoxal bis(butylamidinohydrazone) (MGBB) inhibited S-adenosylmethionine decarboxylase (SAMDC) activity competitively with S-adenosylmethionine (SAM) showing the Ki value of 1.8 X 10(-5) M. MGBB showed less SAMDC-stabilizing effect in rat liver in vivo than did methylglyoxal bis-(guanylhydrazone) (MGBG). Mitoguazone 305-309 adenosylmethionine decarboxylase 1 Homo sapiens 94-99